Last reviewed · How we verify
BMS-986207
At a glance
| Generic name | BMS-986207 |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors (PHASE1, PHASE2)
- Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT (PHASE1, PHASE2)
- COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (PHASE1, PHASE2)
- A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-986207 CI brief — competitive landscape report
- BMS-986207 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI